On Thursday, Goldman Sachs maintained a Neutral rating on Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) with a steady price target of $5.00. The firm highlighted the acquisition of avexitide from Eiger BioPharmaceuticals as a pivotal element in Amylyx's strategy. Avexitide, a GLP-1R antagonist, is set to enter a crucial Phase 3 study in the first quarter of 2025 for post-bariatric hypoglycemia (PBH), with expectations for top-line data to emerge in 2026.
The analyst from Goldman Sachs noted the data thus far largely supports avexitide's potential to benefit patients suffering from PBH. A key point of the positive outlook is the alignment with the FDA on the proposed primary endpoint, which is the reduction of hypoglycemia events, believed to reduce regulatory risks. However, there is an ongoing debate regarding the size of the market opportunity for Amylyx within PBH, as the drug would be the first in its category for this specific indication.
The rarity and unclear prevalence of PBH, which is a complication arising from bariatric surgery, add to the market opportunity debate. Many patients remain asymptomatic, making it challenging to determine the exact market size. Additionally, there are concerns about the future of bariatric surgery given the wide availability of GLP-1R agonists.
Despite these uncertainties, Goldman Sachs' review, combined with discussions with physicians, suggests a significant addressable market exists for new treatments like avexitide. The analyst estimates peak sales for the drug could reach $1 billion, with a probability of success (PoS) placed at 50%. The firm's stance reflects a calculated perspective on Amylyx's potential in the market, considering both the promising aspects of avexitide and the market challenges it may face.
In other recent news, Amylyx Pharmaceuticals has been making strides in its drug development pipeline. Baird analyst Joel Beatty upgraded the company's rating from Neutral to Outperform, reflecting optimism about the acquisition of avexitide, a drug candidate for post-bariatric hypoglycemia (PBH). The firm projects sales of $815 million by 2033 if the drug is approved and estimates a 60% probability of avexitide's approval.
Amylyx also reported significant advancements during their Third Quarter 2024 Earnings Conference Call. The company announced the progression of avexitide into a Phase III trial and the commencement of a Phase I clinical trial of AMX0114 in ALS in Canada. Despite recording a net loss of $72.7 million for the quarter, Amylyx maintains a strong financial standing with $234.4 million in cash and investments.
These recent developments showcase Amylyx's continued focus on treatments for neurodegenerative diseases and endocrine conditions. The company's financial loss is mainly attributed to R&D and SG&A expenses. However, Amylyx anticipates a cash runway into 2026, supporting its pipeline development.
InvestingPro Insights
Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) presents an intriguing investment case, as reflected in the recent Goldman Sachs analysis and supported by InvestingPro data. The company's market capitalization stands at $356.07 million, which is relatively modest considering the potential $1 billion peak sales estimate for avexitide mentioned in the article.
InvestingPro data reveals that AMLX has experienced significant price volatility, with a 131.42% price return over the last three months, contrasting sharply with a -64.47% year-to-date return. This volatility aligns with the market's reaction to developments in Amylyx's pipeline, including the acquisition of avexitide.
An InvestingPro Tip suggests that Amylyx's stock price is trading below its fair value based on analyst price targets, with a fair value of $7.5. This could indicate potential upside if the company's clinical trials, particularly the upcoming Phase 3 study for avexitide, yield positive results.
Another relevant InvestingPro Tip notes that Amylyx has a high return on invested capital, which may reflect efficient use of resources in its drug development efforts. This efficiency could be crucial as the company advances avexitide through clinical trials and potentially to market.
For investors seeking a deeper understanding of Amylyx's financial health and market position, InvestingPro offers additional tips and metrics. Currently, there are 11 more tips available on InvestingPro, providing a comprehensive view of the company's investment potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.